
A replenishable LIS coating that eliminates occlusion and reduces infection on vascular cathetersAward last edited on: 2/14/2024
Sponsored Program
SBIRAwarding Agency
NIH : NHLBITotal Award Amount
$329,254Award Phase
1Solicitation Topic Code
837Principal Investigator
Zheng (Jonathan) ZhangCompany Information
Phase I
Contract Number: 1R43HL162196-01A1Start Date: 9/1/2022 Completed: 8/31/2023
Phase I year
2022Phase I Amount
$322,754Public Health Relevance Statement:
PROJECT NARRATIVE Catheter-related bloodstream infection (CRBSI) and catheter-related thrombosis (CRT) are common complications of central venous catheters (CVCs) and are associated with high mortality, morbidity, and cost. The proposed project aims to apply a novel liquid-impregnated surface (LIS) coating on a peripherally inserted central catheter (PICC; a type of CVC) to eliminate these common complications and demonstrate the safety and the long-term efficacy of the coated devices using a swine model. The coating is formulated with an intravenous feeding ingredient that is replenishable through the catheter lumen for extended performance.
Project Terms:
Achievement; Achievement Attainment; Anatomy; Anatomic; Anatomic Sites; Anatomic structures; Anatomical Sciences; Animals; Biological Assay; Assay; Bioassay; Biologic Assays; Blood; Blood Reticuloendothelial System; Blood Chemical Analysis; Blood Chemical Analyses; blood chemistry; Blood Vessels; vascular; Candida albicans; C albicans; C. albicans; C.albicans; Cardiovascular system; Cardiovascular; Cardiovascular Body System; Cardiovascular Organ System; Heart Vascular; circulatory system; Complement Activation; complement pathway regulation; Complication; Diagnosis; intravenous administration; Electrophysiology (science); Electrophysiology; Neurophysiology / Electrophysiology; electrophysiological; Embolism; Embolus; Environment; Goals; Gram-Negative Bacteria; Gram-Positive Bacteria; Cyclic GMP; Guanosine Cyclic Monophosphate; cGMP; Hospitals; Human; Modern Man; Immune system; allergic/immunologic body system; allergic/immunologic organ system; In Vitro; Infection; Structure of jugular vein; Jugular Veins; Medical Device; Morbidity - disease rate; Morbidity; mortality; Oils; Intravenous Feeding; Intravenous Hyperalimentation; Parenteral Feedings; hyperalimentation; hyperalimentation therapy; Parenteral Nutrition; Patients; Blood Plasma; Plasma Serum; Reticuloendothelial System, Serum, Plasma; Plasma; Polymers; pressure; P aeruginosa; P. aeruginosa; Pseudomonas pyocyanea; Pseudomonas aeruginosa; Safety; Science; S aureus; S. aureus; Staph aureus; Staphylococcus aureus; thrombotic disease; thrombotic disorder; Thrombosis; Triglycerides; Triacylglycerol; Yeasts; Microbial Biofilms; biofilm; Catheters; Healthcare; health care; Thrombus; Treatment Cost; base; Blood specimen; Blood Sample; Peripheral; Surface; Clinical; premature; prematurity; Phase; Physiological; Physiologic; Evaluation; Blood Serum; Serum; fluid; liquid; Liquid substance; Venous; anti-microbial agent; anti-microbial drug; antimicrobial agent; antimicrobial drug; Investigation; Side; microorganism; Upper arm; meetings; copolymer; injection/infusion; Performance; microbial colonization; microbial; Nutrient; novel; Devices; Reporting; Device Removal; Sampling; surface coating; Membrum superius; Upper Limb; Upper Extremity; Thickness; Thick; preventing; prevent; Clotting; Coagulation; Coagulation Process; Address; Antimicrobial resistant; Resistance to antimicrobial; anti-microbial resistance; anti-microbial resistant; resistance to anti-microbial; resistant to anti-microbial; resistant to antimicrobial; Antimicrobial Resistance; Cytokine Activation; device development; instrument development; Device or Instrument Development; in vivo; Patient-Focused Outcomes; Patient outcome; Patient-Centered Outcomes; Monitor; Characteristics; Process; Allergic Reaction; Pathway interactions; pathway; pre-clinical; preclinical; cost; healing; Catheter-related bloodstream infection; clinical efficacy; scale up; antimicrobial; anti-microbial; Implant; implantation; FDA approved; product development; phase 1 study; Phase I Study; improved outcome; Injections; thrombogenesis; thrombogenicity; porcine model; pig model; piglet model; swine model
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00